Literature DB >> 25630872

Ten things you should know about protein kinases: IUPHAR Review 14.

Doriano Fabbro1, Sandra W Cowan-Jacob2, Henrik Moebitz2.   

Abstract

Many human malignancies are associated with aberrant regulation of protein or lipid kinases due to mutations, chromosomal rearrangements and/or gene amplification. Protein and lipid kinases represent an important target class for treating human disorders. This review focus on 'the 10 things you should know about protein kinases and their inhibitors', including a short introduction on the history of protein kinases and their inhibitors and ending with a perspective on kinase drug discovery. Although the '10 things' have been, to a certain extent, chosen arbitrarily, they cover in a comprehensive way the past and present efforts in kinase drug discovery and summarize the status quo of the current kinase inhibitors as well as knowledge about kinase structure and binding modes. Besides describing the potentials of protein kinase inhibitors as drugs, this review also focus on their limitations, particularly on how to circumvent emerging resistance against kinase inhibitors in oncological indications.
© 2015 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25630872      PMCID: PMC4439867          DOI: 10.1111/bph.13096

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  294 in total

Review 1.  Archaeal protein kinases and protein phosphatases: insights from genomics and biochemistry.

Authors:  Peter J Kennelly
Journal:  Biochem J       Date:  2003-03-01       Impact factor: 3.857

Review 2.  Protein kinases--the major drug targets of the twenty-first century?

Authors:  Philip Cohen
Journal:  Nat Rev Drug Discov       Date:  2002-04       Impact factor: 84.694

Review 3.  Ba/F3 cells and their use in kinase drug discovery.

Authors:  Markus Warmuth; Sungjoon Kim; Xiang-ju Gu; Gang Xia; Francisco Adrián
Journal:  Curr Opin Oncol       Date:  2007-01       Impact factor: 3.645

4.  Substrate-selective inhibition of protein kinase PDK1 by small compounds that bind to the PIF-pocket allosteric docking site.

Authors:  Katrien Busschots; Laura A Lopez-Garcia; Carmen Lammi; Adriana Stroba; Stefan Zeuzem; Albrecht Piiper; Pedro M Alzari; Sonja Neimanis; Jose M Arencibia; Matthias Engel; Jörg O Schulze; Ricardo M Biondi
Journal:  Chem Biol       Date:  2012-09-21

5.  Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases.

Authors:  Sandra W Cowan-Jacob; Wolfgang Jahnke; Stefan Knapp
Journal:  Future Med Chem       Date:  2014-04       Impact factor: 3.808

6.  Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

Authors:  Alexa B Turke; Kreshnik Zejnullahu; Yi-Long Wu; Youngchul Song; Dora Dias-Santagata; Eugene Lifshits; Luca Toschi; Andrew Rogers; Tony Mok; Lecia Sequist; Neal I Lindeman; Carly Murphy; Sara Akhavanfard; Beow Y Yeap; Yun Xiao; Marzia Capelletti; A John Iafrate; Charles Lee; James G Christensen; Jeffrey A Engelman; Pasi A Jänne
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

Review 7.  Targeting multidrug resistance in cancer.

Authors:  Gergely Szakács; Jill K Paterson; Joseph A Ludwig; Catherine Booth-Genthe; Michael M Gottesman
Journal:  Nat Rev Drug Discov       Date:  2006-03       Impact factor: 84.694

8.  Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.

Authors:  Wenjun Zhou; Dalia Ercan; Liang Chen; Cai-Hong Yun; Danan Li; Marzia Capelletti; Alexis B Cortot; Lucian Chirieac; Roxana E Iacob; Robert Padera; John R Engen; Kwok-Kin Wong; Michael J Eck; Nathanael S Gray; Pasi A Jänne
Journal:  Nature       Date:  2009-12-24       Impact factor: 49.962

9.  The Concise Guide to PHARMACOLOGY 2013/14: enzymes.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

10.  Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC.

Authors:  Valerie Nelson; Jacqueline Ziehr; Mark Agulnik; Melissa Johnson
Journal:  Onco Targets Ther       Date:  2013-03-05       Impact factor: 4.147

View more
  86 in total

Review 1.  Advances of small molecule targeting of kinases.

Authors:  Norbert Berndt; Rezaul M Karim; Ernst Schönbrunn
Journal:  Curr Opin Chem Biol       Date:  2017-07-18       Impact factor: 8.822

Review 2.  Targeting kinase signaling pathways with constrained peptide scaffolds.

Authors:  Laura E Hanold; Melody D Fulton; Eileen J Kennedy
Journal:  Pharmacol Ther       Date:  2017-02-07       Impact factor: 12.310

3.  Assessing Lysine and Cysteine Reactivities for Designing Targeted Covalent Kinase Inhibitors.

Authors:  Ruibin Liu; Zhi Yue; Cheng-Chieh Tsai; Jana Shen
Journal:  J Am Chem Soc       Date:  2019-04-16       Impact factor: 15.419

4.  Escherichia coli YegI is a novel Ser/Thr kinase lacking conserved motifs that localizes to the inner membrane.

Authors:  Krithika Rajagopalan; Jonathan Dworkin
Journal:  FEBS Lett       Date:  2020-09-13       Impact factor: 4.124

5.  Aminoisoquinoline benzamides, FLT3 and Src-family kinase inhibitors, potently inhibit proliferation of acute myeloid leukemia cell lines.

Authors:  Elizabeth Larocque; N Naganna; Xiaochu Ma; Clement Opoku-Temeng; Brandon Carter-Cooper; Gaurav Chopra; Rena G Lapidus; Herman O Sintim
Journal:  Future Med Chem       Date:  2017-05-11       Impact factor: 3.808

6.  Conformation-Selective Analogues of Dasatinib Reveal Insight into Kinase Inhibitor Binding and Selectivity.

Authors:  Frank E Kwarcinski; Kristoffer R Brandvold; Sameer Phadke; Omar M Beleh; Taylor K Johnson; Jennifer L Meagher; Markus A Seeliger; Jeanne A Stuckey; Matthew B Soellner
Journal:  ACS Chem Biol       Date:  2016-03-01       Impact factor: 5.100

7.  Hepatic NAD(+) deficiency as a therapeutic target for non-alcoholic fatty liver disease in ageing.

Authors:  Can-Can Zhou; Xi Yang; Xia Hua; Jian Liu; Mao-Bing Fan; Guo-Qiang Li; Jie Song; Tian-Ying Xu; Zhi-Yong Li; Yun-Feng Guan; Pei Wang; Chao-Yu Miao
Journal:  Br J Pharmacol       Date:  2016-06-27       Impact factor: 8.739

Review 8.  Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends.

Authors:  Kunal Nepali; Jing-Ping Liou
Journal:  J Biomed Sci       Date:  2021-04-12       Impact factor: 8.410

Review 9.  Diacylglycerol kinases: Relationship to other lipid kinases.

Authors:  Qianqian Ma; Sandra B Gabelli; Daniel M Raben
Journal:  Adv Biol Regul       Date:  2018-09-28

Review 10.  Enzyme Activity Assays for Protein Kinases: Strategies to Identify Active Substrates.

Authors:  Brad A Haubrich; David C Swinney
Journal:  Curr Drug Discov Technol       Date:  2016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.